Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma

Cancer

Volumn 113, Issue 1, 2008, Pages 48-56

  Rivera, Michael ^a   Ghossein, Ronald A ^a   Schoder, Heiko ^a   Gomez, Daniel ^a   Larson, Steven M ^a   Tuttle, R Michael ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Fluorodeoxyglucose positron emission tomography (FDG PET); Histopathologic characterization; Radioactive iodine; Thyroid carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131;

ADULT; AGED; ARTICLE; BIOPSY; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MITOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THYROID CARCINOMA; TUMOR NECROSIS;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; THYROID NEOPLASMS;

EID: 47149102563     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23515     Document Type: Article

References (21)

1. Rosai J, Carcangiu ML, Delellis RA. Tumors of the thyroid gland. In: Rosai J, Sobin LH, eds. Atlas of Tumor Pathology. Vol 5. Washington, DC: Armed Forces Institute of Pathology; 1992:161-182.
2. Rosai J. Poorly differentiated carcinomas of the thyroid: introduction to the issue, its landmarks, and clinical impact. Endocr Pathol. 2004;15:293-296.
3. Akslen LA, Livolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer. 2000;88:1902-1908.
4. Hiltzik D, Carlson DL, Tuttle MR, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis. Cancer. 2006;106:1286-1295.
5. Volante M, Landolfi S, Chiusa L, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns. A clinicopathologic study of 183 patients. Cancer. 2004;100:950-957.
6. Sakamoto A. Definition of poorly differentiated carcinoma of the thyroid: the Japanese experience. Endocr Pathol. 2004;15:307-311.
7. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007; 31:1256-1264.
8. Braga-Basaria M, Ringel MD. Beyond radioiodine: a review of potential new therapeutic approaches for thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1947-1960.
9. Wang W, Larson SM, Tuttle MR, et al. Resistance of [18F]- fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001;11:1169-1175.
10. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18f]fluoro-deoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107-1113.
11. Robbins RJ, Chon J, Fleisher M, Larson SM, Tuttle MR. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab. 2002;87:3242-3247.
12. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Tumors of endocrine organs. In: World Health Organization Classification of Tumors. Lyon, France: IARC Press; 2003:50-77.
13. Volante M, Cavallo G, Papotti M. Prognostic factors of clinical interest in poorly differentiated carcinomas of the thyroid. Endocr Pathol. 2004;15:313-317.
14. Andersen PE, Kinsella J, Loree TR, Shaha AR, Shah JP. Differentiated thyroid carcinoma of the thyroid with extrathyroidal extension. Am J Surg. 1995;170:467-470.
15. Ghossein R, Leboeuf R, Patel KN, et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid. 2007;17:655-661.
16. Bronner M, Livolsi V. Spindle cell squamous carcinoma of the thyroid: an unusual anaplastic tumor associated with tall cell papillary cancer. Mod Pathol. 1991;4:637-643.
17. Wreesmann VB, Ghossein R, Patel KN, et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol. 2002; 161:1549-1556.
18. Tickoo S, Pittas AG, Adler M, et al. Bone metastases from thyroid carcinoma. Arch Pathol Lab Med. 2000;124:1440-1447.
19. Heng HHQ. Cancer genome sequencing: the challenges ahead. Bioessays. 2007;29:783-794.
20. Worsham MJ, Pals G, Schouten JR et al. High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast Cancer Res Treat. 2006;96:177-186.
21. Nikiforov MN, Kimura ET, Ghandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404.